Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...